TY  - JOUR
PY  - 2020//
TI  - Use of medical cannabis to treat traumatic brain injury
JO  - Journal of neurotrauma
A1  - Hergert, Danielle Cara
A1  - Robertson-Benta, Cidney
A1  - Sicard, Veronik
A1  - Schwotzer, Daniela
A1  - Hutchison, Kent
A1  - Covey, Dan P.
A1  - Quinn, Davin
A1  - Sadek, Joseph R.
A1  - McDonald, Jacob
A1  - Mayer, Andrew
SP  - ePub
EP  - ePub
VL  - ePub
IS  - ePub
N2  - There is not a single pharmacological agent with demonstrated therapeutic efficacy  for traumatic brain injury (TBI). With recent legalization efforts and the growing  popularity of medical cannabis, patients with TBI will inevitably consider medical  cannabis as a treatment option. Preclinical TBI research suggests cannabinoids have  neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis  use has consistently shown to have detrimental effects. Our review identified a  paucity of high-quality studies examining the beneficial and adverse effects of  medical cannabis on traumatic brain injury, with only a single Phase III randomized  control trial. However, observational studies demonstrate that TBI patients are  using medical and recreational cannabis to treat their symptoms, highlighting  inconsistencies between public policy, perception of potential efficacy, and the  dearth of empirical evidence. We conclude that randomized controlled trials and  prospective studies with appropriate control groups are necessary to fully  understand the efficacy and potential adverse effects of medical cannabis for TBI.<p />  <p>Language: en</p>
LA  - en
SN  - 0897-7151
UR  - http://dx.doi.org/10.1089/neu.2020.7148
ID  - ref1
ER  -